Scancell (LON:SCLP) Shares Up 4.5% – Still a Buy?

Scancell Holdings plc (LON:SCLP)’s share price rose 4.5% on Tuesday . The stock traded as high as GBX 12.20 ($0.16) and last traded at GBX 12.02 ($0.15). Approximately 1,814,874 shares changed hands during mid-day trading, an increase of 150% from the average daily volume of 725,485 shares. The stock had previously closed at GBX 11.50 ($0.15).

Scancell Price Performance

The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of 61.41. The stock has a 50 day simple moving average of GBX 13.72 and a 200-day simple moving average of GBX 13.63. The firm has a market cap of £111.72 million, a PE ratio of -1,150.00 and a beta of 0.35.

About Scancell

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer.